ITI Pharma and Healthcare Fund

A Sectoral/Thematic Fund scheme from ITI Mutual Fund. Figures below are for the Direct · Growth plan (ISIN INF00XX01BO9).

NAV ₹20.4719 on 16 November 2026.

Expense ratio

Total expense ratio 0.89% a year for the Direct · Growth plan, as AMFI published it on 29 October 2026: base expense ratio 0.58%, brokerage 0.07%, transaction costs 0.00%, statutory levies including GST 0.24%.

Returns and risk

PeriodReturn a yearVolatilityWorst fallSharpeSortino
1 year16.4%14.2%-10.8%0.660.70
3 years20.5%14.4%-17.1%0.940.89
5 years15.4%13.7%-17.7%0.620.60

Too little NAV history for the 10-year figures.

Category rank: 10th of 13 Direct-Growth funds in Sectoral/Thematic Fund — Pharma, by 3-year Sortino ratio.

Largest holdings

No portfolio disclosure from this fund house is on file yet.

Plans

Other funds in Sectoral/Thematic Fund

All 257 funds in Sectoral/Thematic Fund · Compare this fund with another

Past returns are history, not a forecast. XIRRO describes funds and portfolios; it is information, not investment advice.